Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: To evaluate the impact of development of nivolumab monotherapy-induced immune-related adverse events (irAEs) and continuing nivolumab with irAEs on the survival of patients with gastric cancer (GC).
Patients And Methods: Patients with unresectable advanced GC and recurrence after curative resection who received nivolumab monotherapy were included in the study. Survival was compared between patients who did and did not develop irAEs, and between those who continued and discontinued treatment due to irAEs.
Results: Of 110 GC patients, 22 developed irAEs. Grade ≥3 IrAEs included rash and diarrhoea associated with enteritis. Progression-free and overall survival (OS) were significantly better in patients with irAEs than in those without. The overall survival of patients who continued treatment despite irAEs was better than that of those who discontinued treatment.
Conclusion: irAE development was associated with better survival in patients with GC who received nivolumab monotherapy. Continuing nivolumab with appropriate treatment in GC patients with irAEs may improve survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.15626 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.
Haematologica
September 2025
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD,.
Immunotherapies, including cell therapies, are effective anti-cancer agents. However, cellular product persistence can be limiting with short functional duration of activity contributing to disease relapse. A variety of manufacturing protocols are used to generate therapeutic engineered T-cells; these differ in techniques used for T-cell isolation, activation, genetic modification, and other methodology.
View Article and Find Full Text PDFPulmonary Function Test Reference Equations May Affect Classification of Restrictive Lung Disease Severity in Systemic Sclerosis.
Arthritis Care Res (Hoboken)
September 2025
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in systemic sclerosis (SSc), particularly among Black patients. Pulmonary function tests (PFTs) are critical to screen for and monitor SSc-ILD. We examined whether race-specific and race-neutral PFT reference equations impact classification of restrictive lung disease (RLD) severity in Black and White patients with SSc.
View Article and Find Full Text PDFComparative Effectiveness of TAVI Platforms and Surgical Aortic Valve Replacement: A Network Meta-Analysis of Randomized Controlled Trials.
Circ Cardiovasc Interv
September 2025
Keele Cardiovascular Research Group, Keele University, United Kingdom (M.A.M., R.B.).
Background: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR).
Methods: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR.
Short-Course Antibiotic Agent Therapy for Early Ventilator-Associated Pneumonia in Patients with Trauma.
Surg Infect (Larchmt)
September 2025
Department of Surgery, Division of Acute Care Surgery, University of Florida College of Medicine, Gainesville, Florida, USA.
Patients with traumatic injuries who develop ventilator-associated pneumonia (VAP) incur a higher risk of developing multi-drug resistance. Shorter duration of antibiotic agents for early VAP at five days may reduce antibiotic agent exposure without worsening patient outcomes. This retrospective cohort study performed at a Level I Trauma Center included adult (≥16 years old) patients with trauma diagnosed with bronchoalveolar lavage (BAL)-proven early (within four days of intubation) bacterial VAP.
View Article and Find Full Text PDFBackground: Advancements in healthcare have significantly improved the prospect of patients with CHD, with over 97% now surviving adulthood. This growing population requires lifelong care and support to manage their condition. Digital health innovations, such as the "Ask Me Anything" (AMA) tool, aim to empower patients and improve collaboration with clinicians.
View Article and Find Full Text PDF